It looks like you're using an Ad Blocker.
Please white-list or disable AboveTopSecret.com in your ad-blocking tool.
Some features of ATS will be disabled while you continue to use an ad-blocker.
(visit the link for the full news article)
Pfizer Inc. said on Tuesday pivotal-stage trials found that adding its experimental HIV drug maraviroc to a regimen of the best-available drugs resulted in twice as many patients achieving suppression of the virus.
If approved by regulators, maraviroc would be the first in a new class of oral HIV drugs since the introduction of protease inhibitors about 10 years ago, said Dr. Howard Mayer, a Pfizer executive in charge of the drug's development.